secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001193125-25-114926
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q1 revenues $141.4M (+43.6% YoY); GAAP EPS $0.45; reaffirms FY outlook
-------------------------------------------------------------------------------

- Total product revenue $141.4M, up 43.6% YoY; FIRDAPSE $83.7M (+25.3%), AGAMREE $22.0M (from $1.2M).
- GAAP net income $56.7M ($0.45 diluted EPS); Non-GAAP net income $86.6M ($0.68 diluted EPS).
- Cash and equivalents $580.7M as of March 31, 2025; no debt.
- Reaffirms full-year 2025 total revenue guidance of $545M–$565M.
- AGAMREE commercial launch momentum with 1,777.5% YoY revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/0001193125-25-114926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525114926/d892793d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-114926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer